UGT2B7 and sickle cell disease: However, sickle-cell anemia patients with the promotor variant UGT2B7 rs7668282 TT genotype required a lower morphine dose because they had a higher capacity of morphine glucuronidation compared to patients with the UGT2B7 rs7668282 CC genotype [93].